Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027
Novo Nordisk unveils longevity and aesthetics strategy at ADA, but stock languishes as CagriSema approval not expected until…
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EUNovo…
Novo Nordisk’s Two-Front Data Blitz: Oral Wegovy Scores in Weight Loss as MASH Findings Bolster th
Novo Nordisk’s oral semaglutide shows 21.6% weight loss in early responders, but stock remains 45% off highs amid…
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10…
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy® (semaglutide 7.2…
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show…
Novo Nordisk taps start-up for new oral weight-loss drugs
Fresh off the launch of its semaglutide pill, Novo Nordisk has entered a partnership with a start-up…
Novo Nordisk Gains EU Approval for Higher-Dose Weight Loss Treatment
Novo Nordisk has secured a significant regulatory endorsement in Europe for its obesity medication, Wegovy. The European Commission…